Skip to main content
The NCI Community Hub will be retiring in May 2024. For more information please visit the NCIHub Retirement Page:https://ncihub.cancer.gov/groups/ncihubshutdown/overview
close

NCL Method GTA-14

By Stephan Stern, Barry Neun

Hep G2 Hepatocarcinoma Homogeneous Apoptosis Assay

Listed in Datasets | publication by group NCL Protocols

Version 1.0 - published on 04 May 2020 doi:10.17917/BPA7-XK19 - cite this Last public release: 2.0

Licensed under these terms

Description

This protocol describes the monitoring of nanoparticle treated human hepatocarcinoma cells (HepG2) for apoptosis, as part of the in vitro NCL preclinical characterization cascade (1, 2).  The protocol utilizes a fluorescent method to measure Caspase-3/7 activation.  This is a homogeneous assay that does not require cell isolation, as required for HepG2 Hepatocarcinoma Apoptosis Assay (NCL Method GTA-6).

Content List

Cite this work

Researchers should cite this work as follows:

Tags

Recommendations

Powered by ...

NCL Protocols

NCL Protocols group image

When watching a publication, you will be notified when a new version is released.